United States //   News Releases

News Releases

News Releases

Date Title and Summary Additional Formats
Toggle Summary Endologix Completes Patient Enrollment in the Ovation® LUCY Study
First Prospective Study Evaluating EVAR in a Female Population
View HTML
Toggle Summary Endologix to Report Fourth Quarter and Full Year 2016 Financial Results on February 22, 2017
IRVINE, Calif. , Feb. 07, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today details relating to the release of its fourth quarter and full year 2016 financial results, which will take place on Wednesday,
View HTML
Toggle Summary Endologix Announces Appointment of Dan Lemaitre as Chairman of the Board
John McDermott to Continue as Chief Executive Officer IRVINE, Calif. , Feb. 06, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced that its Board of Directors has elected to separate the positions of Chairman
View HTML
Toggle Summary Endologix to Present at Leerink Partners 6th Annual Global Healthcare Conference
IRVINE, Calif. , Feb. 03, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that Vaseem Mahboob , Chief Financial Officer, is scheduled to present at Leerink Partners 6 th Annual Global Healthcare Conference
View HTML
Toggle Summary Endologix Announces Reinstatement of CE Mark for AFX® and AFX2 Endovascular AAA Systems
IRVINE, Calif. , Jan. 25, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced that it received notice from its Notified Body in the European Union that the CE Mark for the AFX® and AFX2 Endovascular AAA
View HTML
Toggle Summary Positive Three-Year Results from the Ovation® European Post Market Registry Presented at 2017 LINC Symposium
IRVINE, Calif. , Jan. 25, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today the presentation of positive 3-year clinical data from the Ovation European Post Market Registry at the 2017 Leipzig Interventional
View HTML
Toggle Summary Endologix Resumes Shipments of All Sizes of AFX®2 Endovascular AAA Systems
Appoints Laura Nagel as Vice President, Global Quality
View HTML
Toggle Summary Endologix to Present at the 35th Annual J.P. Morgan Healthcare Conference
IRVINE, Calif. , Jan. 03, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott , Chief Executive Officer, and Vaseem Mahboob , Chief Financial Officer, are scheduled to present at the 35 th
View HTML
Toggle Summary Endologix Provides Physicians with Updated Information about the AFX® Endovascular AAA System
IRVINE, Calif. , Dec. 30, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today issued a letter to physicians with updated information about the AFX® Endovascular AAA System .
View HTML
Toggle Summary Endologix Resumes Shipments and Procedures with AFX and Some Sizes of AFX2
Schedules Conference Call for December 30, 2016 at 9:00 am ET IRVINE, Calif. , Dec. 29, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today provided an update on the previously announced temporary hold on shipments of
View HTML
Toggle Summary Endologix Announces Temporary Hold on AFX to Resolve a Manufacturing Issue
Conference Call Scheduled for 9:00 am ET Today, December 27, 2016 IRVINE, Calif. , Dec. 27, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced a temporary hold on shipments of its AFX® Endovascular AAA
View HTML
Toggle Summary Endologix Receives Australian Therapeutic Goods Administration (TGA) Approval for AFX®2 Bifurcated Endograft System
IRVINE, Calif. , Dec. 19, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that the Australian Therapeutic Goods Administration (TGA) has approved the AFX®2 Bifurcated Endograft System for inclusion on
View HTML
Toggle Summary Endologix to Participate at the Guggenheim Securities 4th Annual Boston Healthcare Conference
IRVINE, Calif. , Dec. 06, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today it will participate at the Guggenheim Securities 4 th Annual Boston Healthcare Conference in Boston, MA.
View HTML
Toggle Summary Positive Two-Year Data from the Nellix® EVAS FORWARD Global Registry Presented at 2016 VEITH Symposium
IRVINE, Calif. , Nov. 17, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today the presentation of two-year clinical data from the Company's EVAS FORWARD - Global Registry, a post-market study that
View HTML
Toggle Summary Positive Five-Year Results from the Global Ovation® Pivotal Trial Presented at 2016 VEITH Symposium
IRVINE, Calif. , Nov. 16, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today the presentation of positive 5-year safety and effectiveness clinical data from the global Ovation Pivotal Trial at the 2016 VEITH
View HTML